Cellectis

Pfizer Corporation

Allogene Therapeutics, Inc.

Alexandre Juillerat

Philippe Duchateau

Laurent Poirot

Julien Valton

Arvind Rajpal

Barbra Johnson Sasu

Roman Galetto

Thomas John Van Blarcom

Julianne Smith

Tracy Chia-Chien Kuo

Javier Fernando Chaparro Riggers

Jean-Charles Epinat

Brian Busser

Thomas Charles Pertel

Cesar Adolfo Sommer

Claudia Bertonati

George H Silva

Marine Beurdeley

Bijan Andre Boldajipour

Fayza Daboussi

Mohit Sachdeva

Alex Boyne

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

Targeted gene insertion for improved immune cells therapy

A method for engineering less alloreactive immune cells, including T-cells that express chimeric antigen receptors (CARs), using a nucleotide sequence in form of an RNA encoding a anti-TCR CAR to achieve the transient expression of anti-TCR CAR at the cell surface. The transient expression of the anti-TCR CAR recognized by the alpha beta TCR on the cell surface unexpectedly enabled the a purification of the TCR-negative CAR expressing cells. The TCR-negative CAR expressing immune cells can be used in adoptive therapy to treat diseases associated with cell surface antigens, such as cancer with less side effects, in particular less GVHD.

Method for improving production of car T cells

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) into genetically engineered immune cells to prevent cytokine release syndrome to arise during the course of cell therapy. These exogenous coding sequences are more particularly soluble human polypeptides placed under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

Targeted gene integration of CRS inhibitor genes for improved immune cells therapy

Targeted gene integration of NK inhibitors genes for improved immune cells therapy

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Chimeric antigen receptors targeting B-cell maturation antigen

Growing community of inventors

New York, NY, United States of America

Alexandre Juillerat